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The Role of Nonenzymatic Glycation and Carbonyls in
Collagen Cross-Linking for the Treatment
of Keratoconus
Gage Brummer,1,2 Stacy Littlechild,1,2 Scott McCall,1,2 Yuntao Zhang,1
and Gary W. Conrad1,2
PURPOSE. Corneal cross-linking (CXL) is a treatment for kerato-
conus that eliminates the need for keratoplasty in most pa-
tients. However, its molecular mechanisms remain under
study. Advanced glycation end products (AGEs) have been
suggested by many studies as the causative strengthening agent
during CXL, though no studies to date have directly tested this
hypothesis.
METHODS. Corneas of young rabbits and sharks were pretreated
with pyridoxal hydrochloride and copper ions before CXL.
Two known inhibitors of AGE formation, aminoguanidine and
rifampicin, were applied during CXL in the treatment solution.
Tensile strength tests were conducted after these experiments
to detect diminished or accentuated corneal stiffening after
CXL. SDS-PAGE was performed on type I collagen cross-linked
in the absence and presence of AGE inhibitors.
RESULTS. Pretreatment with pyridoxal hydrochloride resulted in
significantly higher corneal stiffening after CXL. AGE inhibitors
significantly diminished cross-linking as detected by both ten-
sile strength measurements using whole corneas and gel elec-
trophoresis of in vitro cross-linking of type I collagen in solu-
tion, in the presence and absence of the inhibitors. Rifampicin
inhibited CXL more significantly than aminoguanidine in gel
electrophoresis and tensile strength tests, confirming recent
findings on its efficacy as an AGE inhibitor.
CONCLUSIONS. Data presented here suggest that CXL is carbonyl
dependent and involves the formation of AGE cross-links. Six
possible cross-linking mechanisms are discussed. (Invest Ophthal-
mol Vis Sci. 2011;52:6363–6369) DOI:10.1167/iovs.11-7585
Corneal cross-linking (CXL) is an effective treatment toreplace keratoplasty and hard contact lenses for treating
patients in the early stages of keratoconus. During CXL, the
deepithelialized cornea is topically “marinated” with riboflavin
solution (RF) for 30 minutes and then irradiated with long-
wavelength ultra-violet light (UVA) for 30 minutes as RF mari-
nation continues.1 The UVA photosensitizes riboflavin, gener-
ating reactive oxygen species thought to be required for the
formation of covalent cross-linking in the corneal extracellular
matrix. These reactive oxygen species also cause the apoptosis
of keratocytes in the anterior half of the corneal stroma.2
Additionally, treatment with UVA is associated with some risk
to other tissues within the eye.3–5 For this reason, it is desirable
to develop protocols that increase the amount of cross-linking
and yet allow a reduction of cytoxic-UVA exposure.
Despite vast clinical knowledge of the applications and
effects of CXL, the exact molecular mechanisms of cross-link-
ing are mostly unknown.6 McCall et al.7 describe the many
chemical interactions that are possible in CXL, pointing out
that collagen fibrils were observed by Wollensak2 to increase in
diameter during CXL. Considering that it has been observed
that an apparently similar increase in collagen fibril size in the
corneal stroma occurs with such normal aging processes as
glycation8 and the fact that the mean age of keratoconus onset
is approximately 15 years and diminishes with age, it seems
possible that age-related reactions, such as nonenzymatic gly-
cation, may occur during CXL. It has also recently been iden-
tified that carbonyl groups and reactive oxygen species are
essential to cross-linking, but the exact molecules involved
remain unknown.7 Recent work indicates that CXL generates
cross-links not only between collagen molecules but also be-
tween proteoglycan core proteins.9
Pyridoxal, the nonphosphorylated form of biologically ac-
tive vitamin B6, has been shown to nonenzymatically convert
free primary amine residues to carbonyl residues by Schiff base
formation between the carbonyl group of pyridoxal and a free
amine residue in the presence of metal ions.10 Reacting the
treated cornea with Brady’s reagent, which stains carbonyls
red, can test for this chemical conversion of an amine to a
carbonyl group. However, pyridoxal and its derivatives are also
strong singlet-oxygen quenchers,11 so their addition to the
riboflavin solution would remove the necessary singlet oxygen
and thus would inhibit UVA-catalyzed cross-linking. Neverthe-
less, if pretreatment with pyridoxal hydrochloride is followed
by extensive rinsing and then CXL (thus removing such singlet-
oxygen quenchers), a stronger cross-linking effect should be
achieved than in achieved with CXL alone because many more
carbonyl groups ought to be present and reactively available.
It is well documented in food science that cross-links slowly
form between proteins and sugars attached to other proteins
through Maillard reactions, also referred to as browning reac-
tions or glycation, thus forming advanced glycation end prod-
ucts (AGEs).12 AGEs form when reactive oxygen species chem-
ically oxidize sugars, to spontaneously condense13 or form
reactive metabolic intermediates, such as glyoxal.14 These re-
active species then form Schiff bases with arginine and lysine
residues in collagen fibrils15 and undergo a set of oxidations,
rearrangements, and reductions to form cross-links in colla-
gen.16 It also has been well documented that reactive oxygen
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species lead to the production of AGEs on specific lysine and
hydroxylysine residues in type I collagen,17 although no stud-
ies to date have tested the possibility of this reaction in CXL.6
AGE cross-links cause the diameters of collagen fibrils in col-
lagenous tissues to increase with aging18 and diabetes,19 both
of which are associated with preventing the onset of kerato-
conus. Collagen fibril diameter is also seen to increase during
CXL,2 suggesting that AGE formation may be involved in CXL.
The corneal stroma contains abundant proteoglycan core
proteins posttranslationally modified with the sulfated polysac-
charide chains glycosaminoglycans (GAGs). These GAGs have
carbonyl groups and sugars along their lengths that are in
potentially reactive proximity to collagen fibrils.20 These sugar-
protein interfaces, which are essential for normal stromal struc-
ture,21 seem likely places for AGE cross-links to form. Even a
small number of such cross-links between such large polymers
as collagen fibrils and proteoglycans can be predicted to have
disproportionately large effects on the tensile strengths of the
corneal stroma in vivo.
Aminoguanidine (AG) and rifampicin (Rif) strongly inhibit
the formation of AGEs,22,23 although Rif exhibits higher inhib-
itory potential than AG.24 Neither of these AGE inhibitors is
known to be capable of breaking preexisting AGE-derived
cross-links.24,25 Rather, they inhibit the formation of new
AGEs, possibly by reacting with the reactive carbonyl groups
that AGE formation produces, thereby disabling the ability of
carbonyl groups to react with amine residues.26 Therefore, if
the mechanism by which CXL causes cross-linking of corneas
involves AGEs or reactive carbonyl groups, then the addition of
an AGE inhibitor to the RF solution should significantly reduce
the amount of cross-linking during CXL. Some of these hypoth-
eses have been tested in the experiments described here.
MATERIALS AND METHODS
Tissue Acquisition and Storage
Whole rabbit eyes were received on dry ice from Pel-Freez Biologicals
(Rogers, AR) and were stored in a 80°C freezer. Rabbit corneas were
excised from still frozen rabbit eyes by first circumcising the sclera
approximately 4 mm from the cornea and then carefully gripping the
4-mmmargin of the sclera with jeweler’s forceps to release the anterior
half of the eye from the still frozen lens surface. Corneas were thawed
in room temperature 1 PBS, pH 7.4, for 2 minutes and subsequently
deepithelialized by gentle scraping with a spatula over the anterior
surface of the cornea. Corneas were then placed in a fresh solution of
1 PBS immediately before treatment.
Whole eyes from dogfish sharks (Squalus acanthias) were ob-
tained from Mount Desert Island Biological Laboratory (Salsbury Cove,
ME). Corneas were shipped, stored, and prepared exactly as were the
rabbit corneas, except 0.53 M NaCl, isotonic to seawater, was used in
place of 1 PBS.
Solution Preparation
Clinical riboflavin solutions were made by first dissolving in 1 PBS
(for rabbit corneas) or 0.53 M NaCl (for shark corneas) enough ribo-
flavin-5-phosphate (Fluka; Sigma-Aldrich, St. Louis, MO) to make a
0.1% wt/vol solution and, in the same solution, dissolving enough
high-molecular weight dextran (Fisher Scientific, Pittsburgh, PA) to
make a 20% wt/vol solution. The control solutions were made similarly
to the process used for dextran, but they contained no riboflavin.
Pretreatment solutions for rabbit corneas were made by dissolving
pyridoxal-hydrochloride (Sigma-Aldrich) in 1 PBS (or in 0.53 M NaCl
for sharks) to yield a 20-mM concentration, and copper sulfate (for
catalysis) to yield a 1-M concentration. This solution was then titrated
to pH 7.4.
Aminoguanidine or Rif was dissolved in the previously described
clinical riboflavin solution or control solution to yield 0.1% (wt/vol),
depending on the designated treatment.
Pyridoxal Hydrochloride Pretreatment
For the pyridoxal pretreatment, freshly prepared corneas were indi-
vidually placed in 50-mL centrifuge tubes containing 15 mL of 20 mM
pyridoxal hydrochloride solution and were incubated gently on a
rocker for 1 hour. After incubation in pyridoxal solution, the corneas
were rinsed free of nonreacted pyridoxal (and also free of the pyridox-
amine predicted to have been produced by transamination) by placing
them on a rocker in 50-mL centrifuge tubes containing 45 mL 1 PBS
or 0.53 M NaCl, pH 7.4, for 15 minutes. This rinsing procedure was
repeated to yield rinsing times of 0.5 hour, 1 hour, 2 hours, and 4
hours, so as to determine the effect of extensive rinsing on biochem-
ical changes in the corneal stroma.
CXL Treatment and Tensile
Strength Measurement
Corneas were draped on the top of ping-pong balls to maintain their
native curvature during treatment. They were then dripped on from 2
cm above with the designated treatment solution at a rate of 10 L/min
delivered by a syringe pump (model NE4000; New Era Pump Systems,
Inc., Wantagh, NY), causing a drop to fall every 1.5 minutes. After 30
minutes, corneas were irradiated with ultraviolet light (365 nm, UVA,
3 mW/cm2) at a distance of 5 cm from the clinical CXL irradiation
apparatus (UV-X Radiation System for CXL; IROC Medical, Zurich,
Switzerland), while dripping continued at the same rate. Regardless of
whether the treatment involved UVA exposure, treatment solution was
dripped onto all corneas for a total of 1 hour. After this treatment,
corneas were quickly rinsed free of the viscous dextran solution in a
Petri dish containing 1 PBS or 0.53 M NaCl. Two-millimeter strips
were cut with a scalpel from the center of the cornea, leaving sclera on
each of the strips. Tensile strength tests were then performed as
described in McCall et al.7 Briefly, these 2-mm corneal strips were
attached at both ends to clamps. One of these clamps was attached to
a force gauge, and the other was attached to an apparatus that moved
away from the force gauge at a constant speed. The strengths reported
were force gauge readings from corneal strips that were destroyed
between the two clamps.
Staining with Brady’s Reagent
Brady’s reagent containing 2,4-dinitrophenylhydrazine (2,4-DNP) was
prepared as described by McCall et al.7 Corneas underwent 1 of 2
treatments: treatment with 1 PBS or 0.53 M NaCl and treatment with
20 mM pyridoxal in 1 PBS or 0.53 M NaCl, in accordance with the
pyridoxal pretreatment regimen. Then each was placed for 5 minutes
in Brady’s reagent with gentle rocking, rinsed in 10 mL of 100%
methanol for 1 minute, placed into 1 N NaOH for 20 seconds, rinsed
again for 1 minute in 10 mL methanol, which then was replaced with
1 PBS or 0.53 M NaCl for 20 minutes, with gentle rocking. Digital
photographs were taken immediately after this treatment.
SDS-PAGE
Sample Preparation. Soluble collagen type I (3 g/L) from
bovine skin was adjusted to pH 7.2. Type I collagen (3 L), pH 7.2, and
1 PBS (7 L) were added to each of the treatment solutions (10 L).
For the collagen control, 10 L of 1 PBS was then added. With the
other treatments, this 10 L of 1 PBS contained twice the desired
concentration of reagents, to yield a final volume of 20 L per treatment
tube and with all reagents in desired final concentrations. Each of these
tubes was then vortexed for 10 seconds and irradiated for 30 minutes at
a distance of 5 cm with the corneal cross-linking radiation system (UV-X;
IROC AG, Zurich, Switzerland) with the top of the solution exposed
directly to the UVA. To ensure homogenous cross-linking, the tubes were
vortexed for 10 seconds every 10 minutes during treatment.
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Sample Analysis. For analysis of collagen cross-linking in
solution, 5 L of 4 sample buffer (NuPAGE LDS; Invitrogen,
Carlsbad, CA) and 2 L of 10 reducing agent (NuPAGE; Invitro-
gen) were added to each sample solution, heated at 70°C for 10
minutes, and loaded onto precast gels (8 cm  8 cm  1.5 mm;
NuPAGE Novex Tris-Acetate Mini 3–8%; Invitrogen) and subjected
to electrophoresis (120 V, 55 minutes) under reducing conditions.
After electrophoresis, the gels were stained with 0.1% (wt/vol)
Coomassie Brilliant Blue R-250 overnight and subsequently de-
stained in distilled water.
RESULTS
Pyridoxal hydrochloride solution initially appeared to oxida-
tively deaminate free amino groups to carbonyl groups on
proteins in the deepithelialized cornea when rinsed for 0.5
hour or 1 hour (Fig. 1). However, after rinsing for 2 hours and
4 hours, staining by Brady’s reagent diminished to control
levels as bound pyridoxal was eluted from the corneal matrix.
Tests of the tensile strengths of pretreated and non-pre-
treated corneas were conducted using both rabbit and shark
corneas (Fig. 2). Strengths of control corneas were all signifi-
cantly lower than those of corneas treated with both RF and
UVA. Pretreatment with pyridoxal hydrochloride solution be-
fore treatment with RF and UVA caused a significant increase
(130% in sharks, 156% in rabbits) in strength over corneas
treated with RF and UVA alone (4.31  0.36 N compared with
5.63 0.53 N in sharks; 6.51 0.31 N compared with 10.16
0.50 N in rabbits;   0.05).
Tensile strength tests also were conducted to test whether
the presence of the AGE inhibitors AG and Rif would cause a
diminution of cross-linking during CXL treatment (Fig. 3). The
FIGURE 1. Results of histochemical staining for the presence of car-
bonyl groups with Brady’s reagent containing 2,4-DNP in rabbit cor-
neas. Rinsing time in 1 PBS is displayed in upper left corners of the
boxes. A positive stain for carbonyl groups is the presence of red-violet
color complexes in the tissue. Complete elution of bound pyridoxal
was seen after 4 hours of rinsing. n  3.
FIGURE 2. Treatments are described on the x-axes. Pyridoxal-hydro-
chloride (PL HCl) and pyridoxal phosphate (PLP) denote pretreatment
with that chemical. Tensile strength of 20 mM PL HCl solution-pre-
treated and control rabbit corneas at pH 7.4. Pretreatment with PL HCl
gave 156% increases in strength over CXL treatment in rabbits and
131% in sharks. Corneas were cut into 2-mm-wide strips after the final
treatment step and were mounted in the apparatus for determining
tissue strength. Controls were not statistically different; n  8 corneal
strips (4 corneas) per group. Error bars are expressed as SEM.
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presence of the inhibitors alone showed no significant altera-
tion of corneal tensile strength compared with controls. How-
ever, on the addition of Rif during CXL treatment, corneal
strengths remained at control levels. The addition of AG during
CXL caused a significant decrease in tensile strength compared
with the addition of CXL alone but did not completely elimi-
nate the strengthening effects of CXL.
Gel electrophoresis was used to determine the effects of
these AGE inhibitors on in vitro CXL of soluble type I
collagen (Fig. 4). In the absence of CXL, control collagen
(lane 2) showed distinct native bands at 130, 250, and 250
kDa, corresponding to 1/2 (monomer),  (dimer), and 
(trimer) chains, respectively. Collagen cross-linked by CXL
(lane 3) alone showed almost complete disappearance of
these bands (cross-linked collagen remained in the sample
well as polymers too large to enter the gel). On the addition
of AG during CXL (lane 4), instead of remaining cross-linked
in the sample well, a significant proportion of the collagen
was cross-linked only to the extent that it migrated as 
chains, and trace amounts remained non–cross-linked as
1/2 and  bands, indicating an inhibition of cross-linking
compared with that seen in the absence of AG (lane 3). The
addition of 3 mM glucose to the AG-inclusive treatment (lane
5) neither increased nor decreased the pattern of inhibited
cross-linking caused by AG. The addition of Rif, a more
powerful inhibitor of cross-linking than AG, almost totally
blocked cross-linking and generated a near-control state
(lane 6), even in the simultaneous presence of 3 mM glucose
(lane 7). As a control, the addition of 3 mM glucose to the
collagen solution during CXL cross-linking (lane 8) caused
only slight inhibition of collagen cross-linking compared
with that seen in its absence (lane 3) as a variety of polymers
approximating the molecular size of  chains appeared, but
1/2 and  molecules were still totally cross-linked into
higher molecular weight forms.
DISCUSSION
Results from the tensile strength tests after pretreatment with
pyridoxal hydrochloride suggest that pyridoxal hydrochloride
changes the biochemical properties of the corneal stroma in a
way that facilitates cross-linking. Increasing the number of
carbonyl groups in the stroma through oxidative deamination
should increase the cross-linking effect of CXL because current
evidence indicates that the process is carbonyl dependent.7
Alternatively, pyridoxal could covalently attach to amino
groups, which can be excited by UV light to form reactive
radical states.27 These reactive radical states could then induce
cross-links with other chemical groups in the stroma. The
initial staining by 2,4-DNP-tests (Brady’s reagent) after pretreat-
ment with pyridoxal hydrochloride and a rinsing time of 0.5
hour or 1 hour indicate that oxidative deamination is occurring
as staining is retained (Fig. 1). However, after 4 hours of rinsing
time, it was clear from Brady staining that the biochemical
change caused by pyridoxal hydrochloride was able to be
reversed by further rinsing. This rinsing effect suggests that
oxidative deamination is not responsible for the increased
FIGURE 3. Tensile strengths of rabbit and shark corneas undergoing
CXL in the presence of the AGE inhibitors Rif and AG. Treatments are
described on the x-axis. Rifampicin shows greater ability to suppress
cross-linking than AG in both sharks and rabbits; n  8 corneal strips
(4 corneas) per group. Error bars are expressed as SEM.
FIGURE 4. Electrophoretic analysis of AGE inhibitors. 9 g collagen/
lane. Lane 1, molecular weight marker; lane 2, collagen alone; lane 3,
collagen  CXL; lane 4, collagen  CXL  AG; lane 5, collagen 
CXL  AG  3 mM glucose; lane 6, collagen  CXL  Rif; lane 7,
collagen  CXL  Rif  3 mM glucose; lane 8, collagen  CXL 
3 mM glucose.
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corneal stiffness on pretreatment with pyridoxal but, rather,
that transiently bound pyridoxal is activated to reactive states
by UV light. The aromatic ring of pyridoxal could react analo-
gously to tyrosine as a target for singlet oxygen, generating
productive cross-links and more reactive species capable of
displaying the observed increase in tissue tensile strength.28,29
Clinical use of a pyridoxal-based pretreatment on the cornea
has not been reported previously for primary effects or poten-
tial side effects, but, because of the 2-hour pretreatment and
the full immersion of the cornea in solution, it is unlikely that
this protocol will have a direct clinical application. This chem-
ical technique could be used in the field of collagen tissue
engineering as a way to selectively enhance cross-linking in
certain areas of the engineered matrices.30,31
Recent clinical studies of CXL already suggest that AGE forma-
tion might be responsible for the strengthening effect from CXL
on the corneal stroma. First, persons with diabetes are less likely
than those without diabetes to develop keratoconus.32 The high
concentrations of blood glucose in diabetic patients causes in-
creased AGE cross-links in many tissues of the body, including the
cornea.33 These cross-links could be providing structural integrity
similar to that of postoperative CXL corneas, which would
thereby reduce the likelihood of keratoconus onset. Second, a
study investigating the smoking habits of keratoconus patients
FIGURE 5. Diagram of proposed cross-
linking mechanisms at the molecular
level in the corneal stroma. Top: stro-
mal structure before singlet-oxygen
generation; bottom: six proposed
chemical modifications to the stroma.
Star: where singlet-oxygen reacts;Dot-
ted line: possible places where modifi-
cation could react. The six possible
mechanisms are as follows: modifica-
tion of sugar residue on GAG chain,
which then reacts with a collagen mol-
ecule (1A) or a proteoglycan core pro-
tein (1B); modification of amino acid
of a proteoglycan core protein, which
then reacts with collagen (2A) or an
adjacent proteoglycan core protein
(2B); modification of an amino acid of
a collagenmolecule, which then reacts
with a proteoglycan core protein (3A)
or an adjacent collagen molecule (3B).
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who underwent CXL showed lower incidence of keratoconus
among smokers compared with non-smokers.34 Cigarette smoke
contains toxic substances that have been shown to increase the
formation of AGEs in several tissues.35
Furthermore, keratoconus tends to appear in patients early
in life, before oxidative stress has produced significant num-
bers of AGE cross-links. These cross-links strengthen the cor-
nea with age, making it more resistant to proteolytic degrada-
tion.36 These AGE cross-links could protect the cornea from
keratoconus in older subjects, which would explain why their
induced formation during CXL inhibits the progression of ker-
atoconus. One common factor linking diabetes, cigarette smok-
ing, and aging is the formation of AGE cross-links. Another
factor linking these three conditions is a reduction of corneal
cortisol content.37
Increased intrafibrillar volume and decreased interfibrillar
spacing of corneal collagen fibrils have been documented in
aging,18 diabetes,19 and CXL.2 These same effects on collagen
organization have been reproduced by inducing glycation in
the rat tail tendon, suggesting that AGE cross-links are respon-
sible for the increased intrafibrillar volume and decreased in-
terfibrillar volume. It has been proposed that this occurs by the
addition of other molecules to the interior domains of the
collagen fibrils by AGE cross-linked glycosaminoglycans,38 thus
increasing the intrafibrillar volume.
The results shown here from the tensile strength tests and
the gel electrophoresis are consistent with the formation of
AGEs during CXL. Increased stiffening, as measured by tensile
strength, was observed in CXL corneas, which is consistent
with stiffening of the cornea resulting from glycation by age-
related processes36 and diabetes. AG and Rif showed different
inhibitory strengths in both the tensile strength and the gel
electrophoresis tests; these data are consistent with a recent
findings showing that Rif is a stronger AGE inhibitor than AG.24
Free glucose in the solution with collagen type I (Fig. 4, lane 8)
inhibited the formation of the highest molecular weight poly-
mers (remaining in the sample well) but allowed the formation
of polymers of approximately -chain size yet did not inhibit
the cross-linking-induced disappearance of the 1/2 and 
chains caused by CXL, suggesting that free glucose in the
corneal stroma might slightly inhibit CXL compared with the
pattern of cross-linking in the absence of free glucose (Fig. 4,
lane 3). CXL may involve any of six possible reactions catalyzed
by the presence of reactive oxygen species among collagen,
proteoglycan core proteins, and glycosaminoglycan chains
(Fig. 5), each of which can now be assessed. Zhang et al.9
demonstrates the role of both collagen and proteoglycan core
proteins in CXL (mechanisms 1B, 2A, 2B, and 3A; Fig. 5).
However, because of the short half-lives of glycosaminoglycan
chains in the corneal stroma and results indicating that they are
unreactive with collagen and proteoglycans during CXL in
vitro,9 it is unlikely that these groups are involved (mecha-
nisms 1A, 1B; Fig. 5).
In conclusion, the data presented here provide additional
evidence implicating carbonyl groups in CXL and the addi-
tional efficacy of pretreatment with pyridoxal on the cross-
linking procedure. The data also suggest a possible practical
technique to increase the strengthening of CXL or to reduce
exposure to cytoxic UVA by pretreating with pyridoxal and
copper ion, though this hypothesis has not been tested. One
negative side effect of adding copper ions is that they could be
involved in Fenton reactions that are deleterious to the
strengthening effects of CXL. Finally, AGE formation could play
a major role in the strengthening effect of CXL, verified by
CXL-producing effects on corneal structure and rigidity similar
to glycation in aging, diabetes, and cigarette smoking.
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